TY - JOUR
T1 - Whole genome sequencing in psychiatric disorders
T2 - The WGSPD consortium
AU - Sanders, Stephan J.
AU - Neale, Benjamin M.
AU - Huang, Hailiang
AU - Werling, Donna M.
AU - An, Joon Yong
AU - Dong, Shan
AU - Abecasis, Goncalo
AU - Arguello, P. Alexander
AU - Blangero, John
AU - Boehnke, Michael
AU - Daly, Mark J.
AU - Eggan, Kevin
AU - Geschwind, Daniel H.
AU - Glahn, David C.
AU - Goldstein, David B.
AU - Gur, Raquel E.
AU - Handsaker, Robert E.
AU - McCarroll, Steven A.
AU - Ophoff, Roel A.
AU - Palotie, Aarno
AU - Pato, Carlos N.
AU - Sabatti, Chiara
AU - State, Matthew W.
AU - Jeremy Willsey, A.
AU - Hyman, Steven E.
AU - Addington, Anjene M.
AU - Lehner, Thomas
AU - Freimer, Nelson B.
N1 - Funding Information:
The authors acknowledge and thank the study participants and their families. The WGSPD is a public–private partnership between the NIMH, the Stanley Center for Psychiatric Research, and researchers at 11 academic institutions across the USA. This work was supported by grants from the NIMH, specifically U01 MH105653 (M.B.), U01 MH105641 (S.A.M.), U01 MH105573 (C.N.P.), U01 MH105670 (D.B.G.), U01 MH105575 (M.W.S., A.J.W.), U01 MH105669 (M.J.D., K.E.), U01 MH105575 (N.B.F., D.H.G., R.A.O.), U01 MH105666 (A.P.), U01 MH105630 (D.C.G.), U01 MH105632 (J.B.), U01 MH105634 (R.E.G.), U01 MH100239-03S1 (M.W.S., S.J.S., A.J.W.), R01 MH095454 (N.B.F.); by grants from the Simons Foundation (SFARI #385110, M.W.S., S.J.S., A.J.W., D.B.G., SFARI #401457 (D.H.G.)); and by a gift from the Stanley Foundation (S.E.H.).
Publisher Copyright:
© 2017 The Publisher.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - As technology advances, whole genome sequencing (WGS) is likely to supersede other genotyping technologies. The rate of this change depends on its relative cost and utility. Variants identified uniquely through WGS may reveal novel biological pathways underlying complex disorders and provide high-resolution insight into when, where, and in which cell type these pathways are affected. Alternatively, cheaper and less computationally intensive approaches may yield equivalent insights. Understanding the role of rare variants in the noncoding gene-regulating genome through pilot WGS projects will be critical to determining which of these two extremes best represents reality. With large cohorts, well-defined risk loci, and a compelling need to understand the underlying biology, psychiatric disorders have a role to play in this preliminary WGS assessment. The Whole Genome Sequencing for Psychiatric Disorders Consortium will integrate data for 18,000 individuals with psychiatric disorders, beginning with autism spectrum disorder, schizophrenia, bipolar disorder, and major depressive disorder, along with over 150,000 controls.
AB - As technology advances, whole genome sequencing (WGS) is likely to supersede other genotyping technologies. The rate of this change depends on its relative cost and utility. Variants identified uniquely through WGS may reveal novel biological pathways underlying complex disorders and provide high-resolution insight into when, where, and in which cell type these pathways are affected. Alternatively, cheaper and less computationally intensive approaches may yield equivalent insights. Understanding the role of rare variants in the noncoding gene-regulating genome through pilot WGS projects will be critical to determining which of these two extremes best represents reality. With large cohorts, well-defined risk loci, and a compelling need to understand the underlying biology, psychiatric disorders have a role to play in this preliminary WGS assessment. The Whole Genome Sequencing for Psychiatric Disorders Consortium will integrate data for 18,000 individuals with psychiatric disorders, beginning with autism spectrum disorder, schizophrenia, bipolar disorder, and major depressive disorder, along with over 150,000 controls.
UR - http://www.scopus.com/inward/record.url?scp=85035331591&partnerID=8YFLogxK
U2 - 10.1038/s41593-017-0017-9
DO - 10.1038/s41593-017-0017-9
M3 - Review article
C2 - 29184211
AN - SCOPUS:85035331591
SN - 1097-6256
VL - 20
SP - 1661
EP - 1668
JO - Nature Neuroscience
JF - Nature Neuroscience
IS - 12
ER -